Loading organizations...
Hava Health, based in Philadelphia, Pennsylvania, United States, develops technology for smoking cessation and nicotine addiction treatment. The company's patent-pending Hale vaporizer and accompanying software are designed to automatically reduce nicotine concentrations over time, positioning itself as a medical treatment rather than a recreational e-cigarette. Hava Health has raised seed funding from venture capital investors including Global Founders Capital, Backstage Capital, and Ben Franklin Technology Partners, though specific amounts have not been publicly disclosed. As of September 2024, the organization was actively pursuing FDA classification for its Hale vaporizer as a smoking cessation treatment, operating from NextFab in Philadelphia. The company was founded by serial entrepreneurs Josh Israel, who serves as CEO, and Devin Serago, with product development active as of 2019.
Hava Health has raised $2.0M across 2 funding rounds.
Hava Health has raised $2.0M in total across 2 funding rounds.
Hava Health has raised $2.0M in total across 2 funding rounds.
Hava Health's investors include Collaborative Seed & Growth Partners, Innovation Works, Bain Capital Ventures, Better Tomorrow Ventures, First Round Capital, Founder Collective, Foundry Group, Hetz Ventures, JLL Spark, Monozukuri Ventures, NextView Ventures, Owl Ventures.
Hava Health has raised $2.0M across 2 funding rounds. Most recently, it raised $50K Seed in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2021 | $50K Seed | — | Collaborative Seed & Growth Partners, Innovation Works | Announced |
| Nov 1, 2019 | $2M Seed | — | Bain Capital Ventures, Better Tomorrow Ventures, First Round Capital, Founder Collective, Foundry Group, Hetz Ventures, JLL Spark, Monozukuri Ventures, NextView Ventures, OWL Ventures, Pareto Holdings, Sequoia Capital, Trajectory Ventures, ULU Ventures, Allen Gannett, David Lieb, JON Brelig, Kevin Weil | Announced |
Hava Health is a portfolio company (digital health device + software) building a controlled nicotine-reduction system — a connected vaporizer plus app — intended to help people quit or reduce nicotine dependence. [3][5]
High‑Level Overview
Hava Health builds a prescription-capable, hardware‑plus‑software nicotine de‑addition system: a flavorless, connected vaporizer (Hale) that dispenses measured nicotine and an app that automates gradual nicotine reduction and behavioral support to increase quit success. [1][3][5]The product serves adults dependent on nicotine who are seeking safer alternatives or structured cessation support, and it is positioned for use in clinical and consumer settings as a low‑risk digital drug therapy. [4][5][8] Growth signals include NIH‑funded research and early public-sector and accelerator partnerships and grants that indicate clinical validation and pilot deployments rather than mass market scale to date. [5][8]
Origin Story
Hava Health was founded to tackle nicotine addiction using a combination of behavioral insights, device engineering, and software automation; company materials and program listings describe a patent‑pending device and app pairing developed by a small founding team with backgrounds in healthcare technology and digital therapeutics (exact founders’ names are not listed in the available public profiles). [3][6][8] The idea emerged from recognizing that nicotine dependence has both chemical and habitual/behavioral components, and that automated, gradual reduction delivered in a clinically controlled way could improve quit rates; early traction includes grants, SBIR/NIH support for trials, and participation in regional innovation programs. [5][8]
Core Differentiators
Role in the Broader Tech Landscape
Hava Health sits at the intersection of digital therapeutics, connected medical devices, and tobacco‑harm‑reduction technology. The company rides several trends: increasing demand for evidence‑based digital health solutions, regulatory pressure and social concern around flavored consumer vaping products, and payer/clinical interest in scalable cessation tools. These forces favor clinically validated, low‑appeal (to youth) alternatives that can be integrated into healthcare workflows. Hava’s emphasis on measurement, NIH research, and automated dosing positions it to align with clinicians and payers seeking demonstrable outcomes rather than mass consumer adoption typical of commercial vape brands.[5][8]
Quick Take & Future Outlook
Hava Health’s next phase is likely focused on clinical validation, regulatory clarity, and payer/clinical partnerships to scale use as a digital therapeutic adjunct for nicotine cessation. If trials funded or supported by bodies like NIH show improved quit rates, Hava could progress toward prescription or medical device pathways and broader clinical rollouts; conversely, commercialization at scale will depend on navigating regulatory requirements for nicotine delivery devices and distinguishing itself from consumer vape products. Given market demand for effective cessation tools and growing emphasis on evidence‑based digital therapeutics, Hava’s clinical-first approach could increase its influence in healthcare delivery for tobacco dependence.[5][8]
If you’d like, I can:
